Next Article in Journal
The Quality of Life of Spanish Patients with Huntington's Disease Measured with H-QoL-I and EQ-5D
Previous Article in Journal
From Population to Public Institutions: What Needs to Be Changed to Benefit from the Full Value of Vaccination
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JMAHP
Volume 4
Issue 1
10.3402/jmahp.v4.30970
jmahp-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Journal of Market Access & Health Policy (JMAHP) is published by MDPI from Volume 12 Issue 1 (2024). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Taylor & Francis.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Feasibility and Attractiveness of Indication Value-Based Pricing in Key EU Countries

by
Mathias Flume
1,
Marc Bardou
2,
Stefano Capri
3,
Oriol Sola-Morales
4,
David Cunningham
5,
Lars-Ake Levin
6 and
Nicolas Touchot
7,* on behalf of Payers’ Insight
1
Kassenärztliche Vereinigung Westfalen-Lippe, Dortmund, Germany
2
CIC INSERM 1432, CHU du Bocage, Dijon, France
3
School of Economics and Management, Cattaneo—LIUC University, Castellanza, Italy
4
Health Innovation Technology Transfer, Barcelona, Spain
5
NHS South East Commissioning Support Unit, London, UK
6
Department of Medical and Health Sciences, Linköping University, Linköping, Sweden
7
groupH, London, UK
*
Author to whom correspondence should be addressed.
J. Mark. Access Health Policy 2016, 4(1), 30970; https://doi.org/10.3402/jmahp.v4.30970
Submission received: 12 January 2016 / Revised: 31 March 2016 / Accepted: 31 March 2016 / Published: 10 May 2016

Abstract

Indication value-based pricing (IBP) has been proposed in the United States as a tool to capture the differential value of drugs across indications or patient groups and is in the early phases of implementation. In Europe, no major country has experimented with IBP or is seriously discussing its use. We assessed how the reimbursement and pricing environment allows for IBP in seven European countries, evaluating both incentives and hurdles. In price setting countries such as France and Germany, the Health Technology Assessment and pricing process already accounts for differences of value across indications. In countries where differential value drives coverage decisions such as the United Kingdom and Sweden, IBP is likely to be used, at least partially, but not in the short-term. Italy is already achieving some form of differential value through managed entry agreements, whereas in Spain the electronic prescription system provides the infrastructure necessary for IBP but other hurdles exist.
Keywords: indication based pricing; drug value; pricing and reimbursement indication based pricing; drug value; pricing and reimbursement

Share and Cite

MDPI and ACS Style

Flume, M.; Bardou, M.; Capri, S.; Sola-Morales, O.; Cunningham, D.; Levin, L.-A.; Touchot, N., on behalf of Payers’ Insight. Feasibility and Attractiveness of Indication Value-Based Pricing in Key EU Countries. J. Mark. Access Health Policy 2016, 4, 30970. https://doi.org/10.3402/jmahp.v4.30970

AMA Style

Flume M, Bardou M, Capri S, Sola-Morales O, Cunningham D, Levin L-A, Touchot N on behalf of Payers’ Insight. Feasibility and Attractiveness of Indication Value-Based Pricing in Key EU Countries. Journal of Market Access & Health Policy. 2016; 4(1):30970. https://doi.org/10.3402/jmahp.v4.30970

Chicago/Turabian Style

Flume, Mathias, Marc Bardou, Stefano Capri, Oriol Sola-Morales, David Cunningham, Lars-Ake Levin, and Nicolas Touchot on behalf of Payers’ Insight. 2016. "Feasibility and Attractiveness of Indication Value-Based Pricing in Key EU Countries" Journal of Market Access & Health Policy 4, no. 1: 30970. https://doi.org/10.3402/jmahp.v4.30970

APA Style

Flume, M., Bardou, M., Capri, S., Sola-Morales, O., Cunningham, D., Levin, L. -A., & Touchot, N., on behalf of Payers’ Insight. (2016). Feasibility and Attractiveness of Indication Value-Based Pricing in Key EU Countries. Journal of Market Access & Health Policy, 4(1), 30970. https://doi.org/10.3402/jmahp.v4.30970

Article Metrics

Back to TopTop